Massive study of 99,000 people tests Paxlovid's Real-World power against severe COVID
NCT ID NCT07261085
First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study looks at health records from about 99,000 adults in Ontario who had COVID-19 and visited a pharmacist. It compares those who got Paxlovid (nirmatrelvir-ritonavir) with those who didn't, to see if the drug lowers the chance of hospitalization, ICU admission, or death within 30 to 60 days. The goal is to understand how well Paxlovid works outside of clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Paxlovid (nirmatrelvir-ritonavir)
What this could lead to
If successful, this study could confirm that Paxlovid effectively reduces severe COVID-19 outcomes in a real-world setting, supporting its continued use.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient health differences. It also only looks at data from Ontario, which may not apply everywhere.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States